“Inhibiting DGKi seems to reverse the effects of cystic fibrosis”
Scientists at the European Molecular Biology Laboratory (EMBL) in Heidelberg and Regensburg University, both in Germany, and the University of Lisboa, in Portugal, have discovered a promising potential drug target for cystic fibrosis. Their work, published online today in Cell, also uncovers a large set of genes not previously linked to the disease, demonstrating how a new screening technique can help identify new drug targets.
Cystic fibrosis is a hereditary disease caused by mutations in a single gene called CFTR. These mutations cause problems in various organs, most notably making the lining of the lungs secrete unusually thick mucus. This leads to recurrent life-threatening lung infections, which make it increasingly hard for patients to breathe. The disease is estimated to affect 1 in every 2500-6000 newborns in Europe.
In patients with cystic fibrosis, the mutations to CFTR render it unable to carry out its normal tasks. Among other things, this means CFTR loses the ability to control a protein called the epithelial sodium channel (ENaC). Released from CFTR’s control, ENaC becomes hyperactive, cells in the lungs absorb too much sodium and – as water follows the sodium – the mucus in patients’ airways becomes thicker and the lining of the lungs becomes dehydrated. The only drug currently available that directly counteracts a cystic fibrosis-related mutation only works on the three percent of patients that carry one specific mutation out of the almost 2000 CFTR mutations scientists have found so far.
Thus, if you were looking for a more efficient way to fight cystic fibrosis, finding a therapy that would act upon ENaC instead of trying to correct that multitude of CFTR mutations would seem like a good option. But unfortunately, the drugs that inhibit ENaC, mostly developed to treat hypertension, don’t transfer well to cystic fibrosis, where their effects don’t last very long. So scientists at EMBL, Regensburg University and University of Lisboa set out to find alternatives.
“In our screen, we attempted to mimic a drug treatment,” says Rainer Pepperkok, whose team at EMBL developed the technique, “we’d knock down a gene and see if ENaC became inhibited.”
Starting with a list of around 7000 genes, the scientists systematically silenced each one, using a combination of genetics and automated microscopy, and analysed how this affected ENaC. They found over 700 genes which, when inhibited, brought down ENaC activity, including a number of genes no-one knew were involved in the process. Among their findings was a gene called DGKi. When they tested chemicals that inhibit DGKi in lung cells from cystic fibrosis patients, the scientists discovered that it appears to be a very promising drug target.
“Inhibiting DGKi seems to reverse the effects of cystic fibrosis, but not block ENaC completely,” says Margarida Amaral from the University of Lisboa, “indeed, inhibiting DGKi reduces ENaC activity enough for cells to go back to normal, but not so much that they cause other problems, like pulmonary oedema.”
The Latest Bing News on:
Cystic fibrosis
- Life transformed for five-year-old... all thanks to wonder cystic fibrosis drugon April 27, 2024 at 6:38 am
EXCLUSIVE: Last year mum Chloe Browne feared her five year-old's cystic fibrosis was slowly destroying his health - but it's all changed after taking wonder pill kaftrio.
- $100B Vertex Pharma Working To Recreate $10B Cystic Fibrosis Success - This Time Focused On Pain Management Drugson April 26, 2024 at 11:34 am
Vertex Pharmaceuticals Inc‘s (NASDAQ:VRTX) blockbuster drug Trikafta for cystic fibrosis (CF) has shown remarkable efficacy, potentially extending the lives of some patients by up to 45 years. Despite ...
- Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Olderon April 26, 2024 at 8:43 am
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of ...
- Its blockbuster cystic fibrosis treatment costs $300,000 a year. Now Vertex wants to solve the opioid crisison April 26, 2024 at 2:00 am
The number of people living with CF worldwide is now 105,000, up from 70,000 in 2012, according to estimates from US non-profit the Cystic Fibrosis Foundation — a rise that experts attribute both to ...
- Woman with cystic fibrosis can’t believe she managed to run 26.2 mileson April 23, 2024 at 11:05 pm
A WOMAN with cystic fibrosis ran the London Marathon thanks to “miracle” drugs. Nell Summerley, 21, from Britwell Salome, took part in Sunday’s race to raise money for the Cystic Fibrosis Trust. She ...
- Vertex has top orphan asset in the pipeline, as pharma eyes shiny obesity drugs: reporton April 23, 2024 at 9:00 pm
Vertex’s cystic fibrosis triple combo is poised to become the top selling orphan drug in terms of net present value, amid shifting sentiments in the pharma industry for rare disease drugs, according ...
- Personal trainer born with cystic fibrosis on mission to run 36 marathons in 36 dayson April 23, 2024 at 7:01 am
Sophie Holmes, from Southend, was told she would not live to be 16 years old after the life-changing diagnosis, but has repeatedly beaten the odds ...
- Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy?on April 23, 2024 at 3:05 am
But Vertex is no longer just about one treatment area. The company last year won approval for a blood-disorder treatment, Casgevy, along with partner CRISPR Therapeutics. And just recently, it made ...
- Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosison April 23, 2024 at 3:01 am
Arcturus Therapeutics is on the verge of obtaining regulatory approvals for two gene therapies targeting rare diseases. See why ARCT stock is a Buy.
- Southend woman with cystic fibrosis to make world record marathon attempton April 20, 2024 at 10:03 pm
A woman with cystic fibrosis is is lacing up to set a new world record by running 36 marathons in 36 days. Sophie Holmes, from Southend-on-Sea, was told her cystic fibrosis (CF) meant she would not ...
The Latest Google Headlines on:
Cystic fibrosis
[google_news title=”” keyword=”Cystic fibrosis” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
The Latest Bing News on:
Cystic fibrosis treatment
- Life transformed for five-year-old... all thanks to wonder cystic fibrosis drugon April 27, 2024 at 6:38 am
EXCLUSIVE: Last year mum Chloe Browne feared her five year-old's cystic fibrosis was slowly destroying his health - but it's all changed after taking wonder pill kaftrio.
- $100B Vertex Pharma Working To Recreate $10B Cystic Fibrosis Success - This Time Focused On Pain Management Drugson April 26, 2024 at 11:34 am
Vertex Pharmaceuticals Inc‘s (NASDAQ:VRTX) blockbuster drug Trikafta for cystic fibrosis (CF) has shown remarkable efficacy, potentially extending the lives of some patients by up to 45 years. Despite ...
- Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Olderon April 26, 2024 at 8:43 am
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of ...
- Its blockbuster cystic fibrosis treatment costs $300,000 a year. Now Vertex wants to solve the opioid crisison April 26, 2024 at 2:00 am
The number of people living with CF worldwide is now 105,000, up from 70,000 in 2012, according to estimates from US non-profit the Cystic Fibrosis Foundation — a rise that experts attribute both to ...
- Walgreens is opening a new pharmacy for cell and gene therapieson April 25, 2024 at 3:38 am
cystic fibrosis and Crohn’s disease. The 18,000-square-foot facility in Pittsburgh will act as a conduit for drug manufacturers, treatment centers and insurance companies, Walgreens said in a release ...
- Best biotech stocks in April 2024on April 23, 2024 at 5:00 pm
Editorial Note: Blueprint may earn a commission from affiliate partner links featured here on our site. This commission does not influence our editors' opinions or evaluations. Please view our ...
- Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosison April 23, 2024 at 3:01 am
Arcturus Therapeutics is on the verge of obtaining regulatory approvals for two gene therapies targeting rare diseases. See why ARCT stock is a Buy.
- If You'd Invested $10,000 in Vertex Pharmaceuticals 5 Years Ago, Here's How Much You'd Have Todayon April 22, 2024 at 4:17 am
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
- Living in the In-Betweenon April 18, 2024 at 8:31 am
Having an atypical presentation of CF means I stand somewhere between the CF world and the rest of the world — and that makes me feel like I belong in neither.
- Report: Europe leads in number of clinical trials for cystic fibrosis, North America for AMLon April 16, 2024 at 2:00 pm
Europe has launched the most clinical trials for cystic fibrosis (CF) treatments, while North America leads in those for acute myeloid leukemia (AML), according to a pair of new global trial landscape ...
The Latest Google Headlines on:
Cystic fibrosis treatment
[google_news title=”” keyword=”cystic fibrosis treatment” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]